Medication-precipitated Seizure in Psychiatric Patients: Typical vs. Atypical Antipsychotics

Author(s): Saeed S. Shafti*

Journal Name: Current Psychopharmacology

Volume 9 , Issue 3 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Backgrounds: It is unknown whether second-generation antipsychotics are safer than first-generation antipsychotics in terms of seizure induction.

Objective: In the present assessment, the relationships between the incidence of seizure attacks among a great sample of non-western psychiatric inpatients and prescribed typical and atypical antipsychotics have been probed and analyzed based on the existing data in the literature.

Methods: Razi psychiatric hospital, as one of the largest and oldest public psychiatric hospitals in the Middle East, had been selected as the field of study in the present retrospective estimation. For assessment, all inpatients that had suffered a seizure during the last sixtyfour months had been included in the current study.

Results: Among seventy-four patients who had experienced seizure attack during the inpatient management, and had been prescribed antipsychotics for symptomatic management of primary psychiatric disorders, 67.56% had received atypical antipsychotic and the remaining (32.43%) had received typical antipsychotics, which revealed a significant quantitative difference between them (p<0.000). Among atypical antipsychotics, olanzapine was the most recommended antipsychotic (33.78%), followed by risperidone (34%), quetiapine (9.45%), and clozapine (n=1, 1.35%). Among typical antipsychotics, too, haloperidol (28.37%) was significantly more prescribed than chlorpromazine (2.70%) and thioridazine (1.35%) (p<0.000). By the way, there was no significant difference, quantitatively, between olanzapine and haloperidol in the present evaluation (p<0.47).

Conclusion: Atypical antipsychotics have comparable potentiality, as typical antipsychotics, for triggering seizure attacks, which demands indispensable cautiousness by clinicians when prescribing such a group of medications for epileptic and neuropsychiatric patients.

Keywords: Atypical antipsychotic, epilepsy, mood disorder, neuropsychiatry, schizophrenia, seizure, typical antipsychotic.

[1]
Kumlien E, Lundberg PO. KumlienPer E. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure 2010; 19(2): 69-73.
[http://dx.doi.org/10.1016/j.seizure.2009.11.005] [PMID: 20036167]
[2]
Bhatti M, Dorriz P, Mehndiratta P. Impact of psychotropic drugs on seizure threshold. Neurology 2017; 88(16): 311.
[3]
Adachi N, Kanemoto K, de Toffol B, et al. Basic treatment principles for psychotic disorders in patients with epilepsy. Epilepsia 2013; 54(1)(Suppl. 1): 19-33.
[http://dx.doi.org/10.1111/epi.12102 ] [PMID: 23458463]
[4]
Okazaki M, Adachi N, Akanuma N, et al. Do antipsychotic drugs increase seizure frequency in epilepsy patients? Eur Neuropsychopharmacol 2014; 24(11): 1738-44.
[http://dx.doi.org/10.1016/j.euroneuro.2014.09.012 ] [PMID: 25453222]
[5]
Hara K, Adachi N, Akanuma N, et al. Effects of antipsychotic drugs on the duration of interictal psychotic episodes in patients with epilepsy. Epilepsy Behav 2013; 27(2): 342-5.
[http://dx.doi.org/10.1016/j.yebeh.2013.02.025 ] [PMID: 23537620]
[6]
Attinger AB, Hermann BP. Psychiatric issues in epilepsy. Neurology 1999; 2: 53.
[7]
Monaco F, Robertson MR. Mood disturbances, psychoses and epilepsy. Epilepsia 1999; 40: 10.
[8]
Torta R, Keller R. Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 1999; 40(10)(Suppl. 10): S2-S20.
[http://dx.doi.org/10.1111/j.1528-1157.1999.tb00883.x ] [PMID: 10609602]
[9]
Sultan S, Chouinard G, Beaudry P. Antiepileptic drugs in the treatment of neuroleptic-induced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14(3): 431-8.
[http://dx.doi.org/10.1016/0278-5846(90)90031-B ] [PMID: 1972802]
[10]
Burke K, Chandler CJ, Starr BS, Starr MS. Seizure promotion and protection by D-1 and D-2 dopaminergic drugs in the mouse. Pharmacol Biochem Behav 1990; 36(4): 729-33.
[http://dx.doi.org/10.1016/0091-3057(90)90068-S ] [PMID: 1977176]
[11]
Kleinlogel H. Spontaneous EEG paroxysms in the rat: effects of psychotropic and alpha-adrenergic agents. Neuropsychobiology 1985; 13(4): 206-13.
[http://dx.doi.org/10.1159/000118189 ] [PMID: 2864656]
[12]
Maurice T, Phan VL, Urani A, Kamei H, Noda Y, Nabeshima T. Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol 1999; 81(2): 125-55.
[http://dx.doi.org/10.1254/jjp.81.125 ] [PMID: 10591471]
[13]
Owens MJ, Risch SC. Atypical antipsychotics Textbook of psychopharmacologyAmerican Psychiatric Association: Washington, DC. 1998; pp. 205-44.
[14]
Hori M, Suzuki T, Sasaki M, Shiraishi H, Koizumi J. Convulsive seizures in schizophrenic patients induced by zotepine administration. Jpn J Psychiatry Neurol 1992; 46(1): 161-7.
[http://dx.doi.org/10.1111/j.1440-1819.1992.tb00829.x ] [PMID: 1353125]
[15]
Long PW. Olanzapine drug monograph. Internet Mental Health 1996.
[16]
Chi SH, Jeong HG, Lee S, Oh SY, Kim SH. Effects of psychotropic drugs on seizure threshold during electroconvulsive therapy Psychiatry Investig 2017; 14(5): 647-55.
[http://dx.doi.org/10.4306/pi.2017.14.5.647] [PMID: 29042890]
[17]
Singh J, Pulman J. Marson, Maguire MJ. Antipsychotics for people with epilepsy and psychosis. Cochrane Database Syst Rev 2014. CD010788
[18]
Kreir M, Van Deuren B, Versweyveld S, et al. Do in vitro assays in rat primary neurons predict drug-induced seizure liability in humans? Toxicol Appl Pharmacol 2018; 346: 45-57.
[http://dx.doi.org/10.1016/j.taap.2018.03.028] [PMID: 29596924]
[19]
Hesdorffer DC. Comorbidity between neurological illness and psychiatric disorders. CNS Spectr 2016; 21(3): 230-8.
[http://dx.doi.org/10.1017/S1092852915000929 ] [PMID: 26898322]
[20]
American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association 2013.
[21]
Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today (Barc) 2003; 39(7): 551-7.
[http://dx.doi.org/10.1358/dot.2003.39.7.799445 ] [PMID: 12973403]
[22]
Barry JJ, Huynh N. Psychotropic drug use in patients with epilepsy and developmental disabilities. In: Devinsky O, Westbrook LE, eds.Epilepsy and developmental disabilities. Butterworth-Heinemann: United States 2001; pp. 205-17.
[23]
Feeney DJ, Klykylo WM. Medication-induced seizures. J Am Acad Child Adolesc Psychiatry 1997; 36(8): 1018-9.
[http://dx.doi.org/10.1097/00004583-199708000-00007 ] [PMID: 9256580]
[24]
Marks RC, Luchins DJ. Antipsychotic medications and seizures. Psychiatr Med 1991; 9(1): 37-52.
[PMID: 1673258]
[25]
Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, García M, Aguirre C. Antipsychotics and seizures: higher risk with atypicals? Seizure 2013; 22(2): 141-3.
[http://dx.doi.org/10.1016/j.seizure.2012.10.009 ] [PMID: 23146619]
[26]
Adelöw C, Andersson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology 2012; 78(6): 396-401.
[http://dx.doi.org/10.1212/WNL.0b013e318245f461 ] [PMID: 22282649]
[27]
Vuilleumier P, Jallon P. [Epilepsy and psychiatric disorders: epidemiological data] Rev Neurol (Paris) 1998; 154(4): 305-17.
[PMID: 9773058]
[28]
Centorrino F, Price BH, Tuttle M, et al. EEG abnormalities during treatment with typical and atypical antipsychotics Am J Psychiatry 2002; 159(1): 109-15.
[http://dx.doi.org/10.1176/appi.ajp.159.1.109] [PMID: 11772698]
[29]
Degner D, Nitsche MA, Bias F, Rüther E, Reulbach U. EEG alterations during treatment with olanzapine Eur Arch Psychiatry Clin Neurosci 2011; 261(7): 483-8.
[http://dx.doi.org/10.1007/s00406-011-0208-4] [PMID: 21431467]
[30]
Kanner AM. Management of psychiatric and neurological comorbidities in epilepsy Nat Rev Neurol 2016; 12(2): 106-16..
[http://dx.doi.org/10.1038/nrneurol.2015.243] [PMID: 26782334]
[31]
Jensen FE. Epilepsy as a spectrum disorder: implications from novel clinical and basic neuroscience. Epilepsia 2011; 52(Suppl. 1): 1-6.
[http://dx.doi.org/10.1111/j.1528-1167.2010.02904.x ] [PMID: 21214533]
[32]
Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003; 16(2): 165-70.
[http://dx.doi.org/10.1097/00019052-200304000-00008 ] [PMID: 12644744]
[33]
Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of epilepsy: a systematic review and meta-analysis. Neurology 2011; 77(10): 1005-12.
[http://dx.doi.org/10.1212/WNL.0b013e31822cfc90 ] [PMID: 21893672]
[34]
Kerr MP, Mensah S, Besag F, et al. International League of Epilepsy (ILAE) commission on the neuropsychiatric aspects of epilepsy. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011; 52(11): 2133-8.
[http://dx.doi.org/10.1111/j.1528-1167.2011.03276.x ] [PMID: 21955156]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 3
Year: 2020
Published on: 04 November, 2020
Page: [228 - 233]
Pages: 6
DOI: 10.2174/2211556009999200606221247
Price: $65

Article Metrics

PDF: 17
HTML: 3